PO150 Memory b cells are key for immunotherapy in multiple sclerosis

Volume: 88
Published: Dec 1, 2017
Abstract
Although multiple sclerosis (MS) is considered to be a CD4+,Th17-mediated autoimmune disease, supportive evidence is largely circumstantial and often based on animal studies. Whilst alemtuzumab inhibits relapsing MS and depletes CD4+ T cells, it also selectively depletes CD19+,CD27+ memory B cells. Although CD4-depletion is considered to have failed in MS, we found following extensive review of the relevant literature and data mining that...
Paper Details
Title
PO150 Memory b cells are key for immunotherapy in multiple sclerosis
Published Date
Dec 1, 2017
Volume
88
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.